Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)

Annals of Hepatology

Volumn 8, Issue 1, 2009, Pages 21-25

  Kalra, Naveen ^a   Duseja, Ajay ^a,c   Das, Ashim ^c   Virmani, Vivek ^a   Dhiman, Radha Krishan ^b   Chawla, Yogesh ^b   Singh, Paramjeet ^a   Khandelwal, Niranjan ^a  

^a Departments of Radiodiagnosis   (India)

^b Department of Hepatology ^*  (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Insulin resistance; MRI; NAFLD; NASH; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Ultrasound

Indexed keywords

ADULT; ARTICLE; BIOCHEMISTRY; BODY MASS; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; HISTOLOGY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; SIGNAL DETECTION; SIGNAL NOISE RATIO;

EID: 62549123749     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31806-x     Document Type: Article

References (30)

1. Falck-Ytter Y, Younossi ZM, Marchesini G, Mc Cullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
3. Talwalkar JA. Motion - all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol 2002; 16: 718-21.
4. Laurin J. Motion - all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol 2002; 16: 722-6
5. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
6. Steering Committee of the Western Pacific region of the World Health Organization. The International Association for the study of Obesity and the International Study Task Force. The Asia- Pacific perspective; redefining obesity and its treatment, 8-56. Australia: Health Communications; 2000.
7. Dhiman RK, Duseja A, Chawla Y. Asians need different criteria for defining overweight and obesity. Arch Intern Med 2005; 165: 1069-70.
8. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications - Part 1: Diagnosis and classification of diabetes mellitus, 31-3. Geneva: World Health Organization; 1999.
9. Expert panel on detection evaluation and treatment of high cholesterol in adults. Executive summary of the third report of the national Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment panel III). JAMA 2001; 285: 2486-97.
10. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 16:1413-9.
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander - Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94: 2467-74.
12. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
13. Duseja A, Das A, Das R, et al. Clinicopathological profile of Indian patients with nonalcoholic fatty liver disease is different from the west. Dig Dis Sci 2007; 52: 2368-74.
14. Duseja A, Das A, Dhiman RK, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007; 6: 222-6.
15. Duseja A, Thumburu KK, Das A, et al. Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol 2007; 26: 170-3.
16. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. BMJ 1986; 292: 13-5.
17. Dixon WT. Simple proton spectroscopic imaging. Radiology 1984; 153: 189-94.
18. Ratziu V, Giral P, Chalotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
19. Dixon JB, Bhathal PS, O'Brian PE. Non-alcoholic fatty liver disease predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
20. Ratziu V, Lecalvez S, Imbert Bismut F, et al. Diagnostic value of bio-chemical markers (fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatology 2003; 38: S510A.
21. Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images; correlation with histology in diffuse liver disease. Invest Radiol 2000; 35: 319-24.
22. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8.
23. Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver on contrast enhanced helical CT AJR. Am J Roentgenol 1998; 171: 659-64.
24. Levenson H, Greensite F, Hoefs J, et al. Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5T vs biopsy. AJR Am J Roentgenol 1991; 156: 307-12.
25. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 1997; 15: 287-93.
26. Fishbein MH, Stevens WR. Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver. Pediatr Radiol 2001; 31: 806-9.
27. Hussain HK, Chenevert TL, Londy FJ, et al. Hepatic fat fraction: MR imaging for quantitative measurement and display- early experience. Radiology 2005; 237: 1048-55.
28. Fishbein M, Castro F, Cheruku S, et al. Hepatic MRI for fat quantification. Its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005; 39: 619-25.
29. Radetti G, Kleon W, Stuefer J, Pittschieler K. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr 2006; 95: 833-7.
30. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.